Intelligence · Drug directory
Oncology Drugs Directory
Anticancer agents, immuno-oncology biologics, targeted therapies, and oncology pipeline compounds tracked across FDA, EMA, and congress readouts.
Quick answer
Oncology drugs: NovaPharmaNews indexes 5 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. Anticancer agents, immuno-oncology biologics, targeted therapies, and oncology pipeline compounds tracked across FDA, EMA, and congress readouts.
-
dabrafenib mesylate
TAFINLAR
-
anti-melanoma mab fragments
TECNEMAB K1
V09IA02 -
autologous glioma tumor cell lysates (inactivated)
SITOIGANAP
L01XX -
dabrafenib
TAFINLAR Novartis Pharmaceuticals
L01EC02 -
dabrafenib mesilate
TAFINLAR INITIAL APPROVAL
Frequently asked questions
How many oncology drugs are in the directory?
5 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.
How are drugs assigned to a therapeutic area?
Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.